Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
about
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusSodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects.Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesRandomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.Dapagliflozin efficacy and safety: a perspective review.DapagliflozinDapagliflozin for the treatment of type 2 diabetes: a review of the literatureDapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Dapagliflozin in patients with type 2 diabetes mellitus.Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trialsSGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysisLong-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III StudiesSGLT-2 inhibitors and their potential in the treatment of diabetes.Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes MellitusEffects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin.Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus.SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation.Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.Dapagliflozin combination therapy in type 2 diabetes mellitus.Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus.Durability of response to dapagliflozin: a review of long-term efficacy and safety.The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.
P2860
Q26782225-7152A691-494B-4562-B522-F22E2B632352Q26864336-516F6032-B6B3-4F7C-B501-A51E9C2443A6Q28079134-84500987-54CE-4BBB-812F-680996B7B7CCQ30248634-9DF3C433-4E57-4C90-A2CE-652C8784D44EQ30877953-909F6206-5F75-4F7C-AFE2-D87292B9A6ECQ33771405-59B0C2FF-4878-4CD7-BB51-2F5BB20C3216Q33885732-2A9E78F0-AC06-44CC-B463-2BCCBA556D07Q34198692-46D76BE7-F3A9-4C3D-AF6C-BA74AF37B523Q34438769-1F842653-27D7-4FFA-8013-33D1DF1B1617Q34514280-4669D916-D031-43F3-A6F6-010F66FF53B0Q34613015-0CF3CF40-0C4E-419B-9F38-9CE626909A59Q34710819-8732968A-C98D-4269-B93F-09A5F4C99457Q35014111-5FD344FE-DBA0-448C-BC29-87F57A1F74C9Q35064363-3DEAE1F5-7A13-41E4-88E0-BF63F696461BQ35068181-2CE2113E-7E01-4827-BC9A-5E65C3BFA48EQ35906490-199D4E9B-A2C0-46A1-A3B8-1C77961DC8E3Q36599869-9E6EFEBD-DC4C-4943-BEFF-5464FFE2CE9FQ37030680-CC789FDF-0A13-4691-8940-50A30FB6F950Q37075620-1A38E6FC-28AA-438F-9EBF-B777F8A57C7AQ37359631-262D6101-4D38-4FDC-B8FF-4D3767C6CA87Q37468412-621AB342-2377-4C77-8862-C9AA63C92B48Q37559899-6408E8AD-12F5-4844-9E6B-E04E26B257BCQ37612158-97A9AFC3-F15E-4A5B-96ED-09C4F522BBE3Q37729725-8734A750-E84F-451F-A5FE-605CA4A85001Q38151450-7F745606-683B-41D2-B2D7-A2BB7D2FB0EAQ38176145-ADA9415E-699B-4F70-A20A-80CE182B9FA7Q38215995-D751D53F-772F-4753-BB02-82C5ED23E652Q38327614-420E3C1C-DF0C-495A-A263-17BA1C6C7A74Q38386194-AD2D099C-42E0-4346-90B0-F9013794EB43Q38602771-BA77A716-58EB-4EF9-9749-0DF1A8508AC7Q38634051-C1DB1BFB-FA64-4CAA-B72E-E958173CCDE0Q38645792-302AFAD2-07A3-41E1-95DE-7918E7F8FD99Q38654762-D33C0A3F-3782-4D8C-8ED6-6B07791FB5A2Q38802437-1CCB9784-7EF5-473C-9A0D-996ACC9A7E1FQ38908779-3CFC5150-01AC-4C6D-87C0-2D33BC116D24Q39170860-78316946-68B1-41B9-9B7D-BCFF3D1EE54BQ39300071-78263AFB-4800-4E41-AEB2-14085E25581EQ39430445-23C5B886-2E5D-47A1-B9C5-0607CBDD20CDQ39629318-ED224193-FEF5-4298-AD02-10C80C3AC8D4Q39865389-362BB685-8665-4FBE-B45C-2D0D635FB45F
P2860
Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Dapagliflozin monotherapy in d ...... olled trial of low-dose range.
@en
Dapagliflozin monotherapy in d ...... olled trial of low-dose range.
@nl
type
label
Dapagliflozin monotherapy in d ...... olled trial of low-dose range.
@en
Dapagliflozin monotherapy in d ...... olled trial of low-dose range.
@nl
prefLabel
Dapagliflozin monotherapy in d ...... olled trial of low-dose range.
@en
Dapagliflozin monotherapy in d ...... olled trial of low-dose range.
@nl
P2093
P1476
Dapagliflozin monotherapy in d ...... olled trial of low-dose range.
@en
P2093
P304
P356
10.1111/J.1463-1326.2012.01659.X
P577
2012-07-24T00:00:00Z